Hooray. Following a sustained campaign on this website and on X by shareholder Nicholas Slater the greedy bastards running Aptamer (APTA) have rowed back on an option scheme that shamed AIM.
The big scandal at biotech dog Aptamer (APTA) is how management have been handed options giving them, potentially, 25% of the equity at just 0.1p in a structure agreed when it was doing a placing at 0.6p c/o the scholars and gentlemen at Turner Pope. I outlined why this is grotesque and smells worse that Neill Ricketts' collection of used Gloucester Rugby Club jockstraps HERE. But there is worse.
Of course certain batshit crazy reporters at news organisations that cover up their role in a criminal enterprise to harass an investigative journalist exposing fraud think that AIM’s problems are caused by … the investigative journalist. But Aptamer (APTA) has news today which screams at investors to abandon the Casino. By way of background, shares in this “ developer of next-generation synthetic Optimer binders” , whatever that means, are at 0.4p down 62.27% YTD and 99.69% over 5 years since an IPO valuing this crock at £80.7 million. So, shareholders have been raped. On the other hand…
Describing itself as a “developer of next‑generation synthetic binders for the life sciences industry”, Aptamer Group (APTA) has issued a “Rapid testing programme for fortified foods” announcement including that it a “collaboration with Imperial College London to translate Aptamer’s folic acid Optimers into rapid testing kit for monitoring food fortification. Programme supported by the Gates Foundation… No rapid test kits currently exist for measuring folate levels in fortified foods at the point of production… Many lower-income countries rely on food fortification programmes as a primary public health intervention”. What about the shares currently rising to 0.55p, a £19 million market cap, in response?
Describing itself as a “developer of next-generation synthetic binders for the life sciences industry”, Aptamer Group (APTA) has announced results for its half-year ended 31st December 2025 headlined “Revenue growth, solid cash position and strong technical progress”… and also announced a “Proposed Placing, Subscription and Retail Offer”. With the shares falling to 0.625p in response, what’s going on?
Describing itself as a “developer of next-generation synthetic binders for the life sciences industry”, Aptamer Group (APTA) has announced a “licensing agreement with Alphazyme” and what about a current 0.975p share price in response, approaching 22% higher?
Describing itself as a “leading developer of next-generation synthetic binders delivering innovation to the life science industry”, Aptamer Group (APTA) has issued an “AGM Statement” including emphasising “sustained commercial momentum and strategic progress” and “an impressive uplift in share price and total market cap over this past 12 months, positioning itself firmly as an established small-cap life-sciences company listed on the AIM market”. What of this, with the shares currently at 0.85p?
Self-described “developer of next-generation synthetic binders for the life sciences industry”, Aptamer Group (APTA) has issued a “Strong contract wins build commercial momentum”-titled announcement following a “New contract with top five pharma company” announcement last week. Do these represent material commercial momentum or are they more attempted ramptastic?
Most recently on “developer of next-generation synthetic binders delivering innovation to the life sciences industry” Aptamer Group (APTA), last week with the shares rising above 1p I concluded that, at least ahead of full-year results detail, to be particularly wary of attempted ramptastic here and still avoid/sell. It has now announced results for its year ended 30th June 2025, with they headlined “Significant commercial progress, expanded licensing portfolio, and strengthened financial position”… and what of the shares in response currently at 0.875p, more than 11% lower?
Describing itself as “a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry”, Aptamer Group (APTA) has issued a “Major top 3 global pharma contract win”-titled announcement and what of the shares currently more than 15% higher at 1.1p in response?
Describing itself as a “developer of next-generation synthetic binders for the life sciences industry”, Aptamer Group (APTA) has announced a “New contract with Metir plc”, stating this is for “binders for the rapid detection of Cryptosporidium parvum oocysts… with Metir plc (AIM: MET), the leading global provider of mobile and point-of-use water and environmental testing technology”. A significant new contract then?
Describing itself as a “leading developer of next-generation synthetic binders delivering innovation to the life science industry”, Aptamer Group (APTA) has today announced “Biomarker Discovery Service Launch” and what of the shares currently 23.5% higher to above 1p in response?
Describing itself as a “leading developer of next-generation synthetic binders delivering innovation to the life sciences industry”, Aptamer Group (APTA) has issued an “Update on licensing and development progress”-titled announcement headlined “Multiple enzyme modulation licensing opportunities and commercial validation from top five pharmaceutical partner”. What about this relative to a current more than 15% higher share price response to 0.725p?
Although it describes itself as a “leading developer of next-generation synthetic binders delivering innovation to the life science industry” most recently writing on Aptamer Group (APTA), in December with the shares up to 0.36p I cautioned to be very wary of attempted ramptastic here. The shares reached 0.45p early this year and most recently closed at 0.38p… and now a placing stated to “enable the company to accelerate the commercialisation of its Optimer technology, further develop its intellectual property portfolio, and advance its licensing pipeline”. Hmmm, on what terms and how significantly so?
Aptamer Group (APTA) has issued “Grant of Options and Director Fee Shares” and director share dealings announcements, and what of the shares currently responding more than 22% higher to 0.36p?
Aptamer Group (APTA) has issued a “Technical Update” announcement emphasising “strong technical progress across key projects with global blue-chip partners” Unilever, Neuro-Bio and AstraZeneca. However, with also an upcoming “investor webinar” and this latest just the week after an AGM update, attempted ramptastic?
